Evidence map›Paper›PMID 29642214›Full record

ArticleMedicine2018

Successful treatment of plasma exchange for rapidly progressive interstitial lung disease with anti-MDA5 antibody-positive dermatomyositis: A case report.

Yushiro Endo, Tomohiro Koga, Takahisa Suzuki, Kazusato Hara, Midori Ishida, Yuya Fujita, Sosuke Tsuji, Ayuko Takatani, Toshimasa Shimizu, Remi Sumiyoshi and 12 more

Open access · goldAbstract readCase Reports
In one paragraph

Article in Medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
4.5field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 43 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 2 institutions in 1 country.

Yushiro EndoDepartment of Rheumatology, Unit of Advanced Preventive Medical Sciences, Graduate School of Bio-medical Sciences, Nagasaki University Department of Rheumatology, Japan Red Cross Nagasaki Genbaku Hospital, Nagasaki Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Tokyo, Japan.
Tomohiro Koga
Takahisa Suzuki
Kazusato Hara
Midori Ishida
Yuya Fujita
Sosuke Tsuji
Ayuko Takatani
Toshimasa Shimizu
Remi Sumiyoshi
Takashi Igawa
Masataka Umeda
Shoichi Fukui
Ayako Nishino
Shin-Ya Kawashiri
Naoki Iwamoto
Kunihiro Ichinose
Mami Tamai
Hideki Nakamura
Tomoki Origuchi
Masataka Kuwana
Atsushi Kawakami
Nagasaki University · JPNippon Medical School · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

rationaleAs the initial treatment of rapidly progressive interstitial lung disease (RPILD) with antimelanoma differentiation-associated gene 5 antibody (anti-MDA5 Ab)-positive dermatomyositis (DM) patients, a combination of corticosteroids, cyclophosphamide, and calcineurin inhibitor is recommended. However, some of these patients have poor prognoses despite such intensive treatment. Other more effective treatments are desired. We report the case of an anti-MDA5 Ab-positive DM patient who had developed RPILD despite intensive treatments; she was treated successfully by a short-term plasma exchange (PE). PATIENT CONCERNS: A 71-year-old Japanese woman was admitted to the rheumatology department of another hospital with progressive muscle weakness of the limbs and erythema on both upper eyelids and the fingers of both hands. She was suspected of having classical DM (CDM) based on the findings of typical skin and myositis. Although a chest computed tomography (CT) examination showed no findings of interstitial pneumonia at the first visit to the department, she newly presented interstitial pneumonia during her admission and her anti-MDA5 Ab titer was elevated. DIAGNOSES: She was diagnosed with interstitial lung disease (ILD) with anti-MDA5 Ab-positive DM.

interventionsShe was treated with 1000 mg of methyl-prednisolone pulse, 500 mg of intravenous cyclophosphamide therapy (IVCY) followed by prednisolone 40 mg/day with tapering, and oral cyclosporine 200 mg/day. However, her interstitial pneumonia worsened with increasing breathing difficulty and an increasing serum ferritin level. She was transferred to our department, and we initiated PE as an additional treatment. OUTCOMES: After the PE treatment, all laboratory findings, for example, ferritin, KL-6, and the titer of anti-MDA5 Ab showed marked improvement, and the patient's skin symptoms and active interstitial pneumonia were relieved. LESSONS: Our patient's case suggests that PE may be effective for RPILD in anti-MDA5 Ab-positive DM patients.

Indexed as

AgedAutoantibodiesCombined Modality TherapyCyclophosphamideCyclosporineDermatomyositisDisease ProgressionFemaleFerritinsHumansInterferon-Induced Helicase, IFIH1Lung Diseases, InterstitialMethylprednisoloneMucin-1Plasma ExchangePrednisoloneAutoantibodiesCyclophosphamideCyclosporineFerritinsIFIH1 protein, humanInterferon-Induced Helicase, IFIH1MethylprednisoloneMUC1 protein, humanMucin-1Prednisolone

Identifiers

PMID29642214
PMCPMC5908626
OpenAlexW2803999586

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.